AI-Powered coaching aims to tame metabolic syndrome

NCT ID NCT07410325

Recruiting now Disease control Sponsor: National University Health System, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a program called LIGHTER-MetS that combines health coaching with an AI-powered app to help people with metabolic syndrome eat better and lower their heart risk. About 316 adults aged 21-65 with metabolic syndrome will join. They will work with a health coach for 3 months and use the eTRIP© app to track meals and activity. The goal is to see if this approach improves self-regulation of eating and reduces cardiovascular risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LIGHTER-MetS program (health coaching plus eTRIP© app)
What this could lead to: If successful, this program could offer an effective, scalable way for people with metabolic syndrome to improve their eating habits and lower their heart disease risk.
What could go wrong: This is a relatively small, early-stage study (316 participants) testing a behavioral intervention, so results may not apply broadly. Success depends on participants consistently using the app and coaching.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC SYNDROME METABOLIC SYNDROME (METS)

Contacts and locations

Locations

National University of Singapore
RECRUITING

Singapore, 117597, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.